Clinical trial NCT04886310: Peabody Developmental Motor Scale-2 in 0 - 24 Months in Turkey
Official title: Turkish Validity and Reliability Study of Peabody Developmental Motor Scale-2 in Infants Aged 0 - 24 Months
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Motor Development
Infant, Premature, Diseases
Keywords: validity
Peabody Developmental Motor Scale II (PDMS-2)
motor development
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2021-05-14
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infants between 0-24 months (adjusted age for premature infants will be calculated),who are followed as neurologically and developmentally at risk infants

Brief summary: This study is the determination of the Turkish version of the Peabody Developmental Motor Scale-2 and its Turkish validity reliability in infants age between 0 - 24 months and to spread its use for evaluation in early rehabilitation in our country.

Detailed description: There are developments in the field of diagnosing children with a high risk of developmental disorders such as cerebral palsy (CP), mental problems and autism spectrum disorder in infancy . In particular, in infants experiencing the onset of extrauterine life in the neonatal intensive care unit, the combination of neonatal neuroimaging along with the assessment of general movements results in a highly accurate prediction of CP .A clinical tool often used in predictions is a neurological examination. Various standard variants are available, such as the Hammersmith Infant Neurological Examination (HINE), Alberta Infant Motor Scale (AIMS). PGMS-2 was developed by Folio and Fewell (2000) to determine the gross and fine motor development levels of children from birth to 71 months. The scale can be used for both children with healthy development and children with special needs. In the development of the Peabody Developmental Motor Scale (PGMS), which is the original version of PGMS-2 used in this study, a developmental structure was adopted instead of sticking to a certain theoretical perspective. PGMS is the first nationally standardized assessment tool that gives gross and fine motor scores separately in the United States of America (USA).This study is the determination of the Turkish version of the Peabody Developmental Motor Scale-2 and its Turkish validity reliability in infants age between 0 - 24 months and to spread its use for evaluation in early rehabilitation in our country.

Eligibility criteria: Inclusion Criteria:

* Infants between 0-24 months (adjusted age for premature infants will be calculated),who are followed as neurologically and developmentally at risk infants
* Infants who are not in neonatal intensive care unit

Exclusion Criteria:

* Infants with congenital heart problems
* Infants of families who do not accept the study
* Infants with musculoskeletal system anomaly
* Infants connected to respiratory equipment

Primary outcomes:
measure: Peabody Developmental Motor Scale II (PDMS-2)
timeFrame: 45-60 minutes
Secondary outcomes:
measure: The Alberta Infant Motor Scale (AIMS)
timeFrame: 30-40 minutes
measure: Hammersmith Infant Neurological Examination (HINE)
timeFrame: 30-45 minutes
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Nilay Çömük Balci
state: Atakum
Study officials:
affiliation: Ondokuz Mayıs University
name: NILAY ÇÖMÜK BALCI, Pt,PhD
role: PRINCIPAL_INVESTIGATOR
References: